ICBio-Initiative

Executive Summary

ICBio-Initiative (ICBio CRO) is a full-service contract research organization headquartered in Bengaluru, India, providing clinical trial services from Phase I to IV, with a strong focus on bioavailability/bioequivalence (BA/BE) studies and bioanalytical research. Established in 2008, the company operates a state-of-the-art clinical facility featuring over 100 beds and advanced LC-MS/MS and ICP-MS instrumentation. ICBio serves a broad client base spanning pharmaceutical, biopharmaceutical, herbal/nutraceutical, medical device, and cosmetic companies, with particular strength in generic and biosimilar drug development. Its broad therapeutic coverage and end-to-end capabilities position it as a versatile partner for sponsors seeking cost-effective clinical development solutions in India. With a team of 50–200 employees, the company has built a reputation for reliable delivery and regulatory compliance, though it operates in a competitive landscape with many established CROs. ICBio's private status and lack of disclosed funding suggest a focus on organic growth and operational efficiency. The company is well-positioned to benefit from increasing demand for outsourced clinical services in emerging markets, especially for generic and biosimilar studies requiring robust BA/BE and bioanalytical expertise.

Upcoming Catalysts (preview)

• TBDMajor Contract Win for Biosimilar BA/BE Studies60% success
• Q2 2026Expansion of Clinical Facility or Capacity Addition70% success
• TBDUSFDA or EU Regulatory Inspection Clearance50% success